ReviewFrontiers in molecular neuroscience2022
Modeling Brain Tumors: A Perspective Overview of
Review in Frontiers in molecular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening.Nature protocols · 2026Review
- Decoding and Overcoming Temozolomide Resistance Through CRISPR/Cas Technologies.Molecular diagnosis & therapy · 2026Review
- Fluorescently engineered KRAS-mutant organoids as versatile tools for in vitro and in vivo cancer modeling.Biochemistry and biophysics reports · 2026Article
- Organoids as next-generation models for investigating intracranial tumours.Molecular brain · 2026Review
- Beyond the mouse: 3R-guided alternative animal models transforming cancer research.Molecular cancer · 2026Review
- Scattering-enabled epi-quantitative phase imaging reveals subcellular detail in organoids and deep mouse brains.bioRxiv : the preprint server for biology · 2026Article
- Modeling pediatric brain tumors with human stem cells.Frontiers in cellular neuroscience · 2026Review
- Article
- Current Landscape of Preclinical Models for Pediatric Gliomas: Clinical Implications and Future Directions.Cancers · 2025Review
- Bridging the gap between tumor and disease: Innovating cancer and glioma models.The Journal of experimental medicine · 2025Review
- Brain tumors and induced pluripotent stem cell technology: a systematic review of the literature.Annals of medicine and surgery (2012) · 2025Article
- Current preclinical models of brain metastasis.Clinical & experimental metastasis · 2024Review
- Modeling of brain tumors usingHeliyon · 2024Review
- Speeding up Glioblastoma Cancer Research: Highlighting the Zebrafish Xenograft Model.International journal of molecular sciences · 2024Review
- Evaluating cell culture reliability in pediatric brain tumor primary cells through DNA methylation profiling.NPJ precision oncology · 2024Article
- Patient-Derived Models of Cancer in the NCI PDMC Consortium: Selection, Pitfalls, and Practical Recommendations.Cancers · 2024Review
- Organoids as a new approach for improving pediatric cancer research.Frontiers in oncology · 2024Review
- Advances and Applications of Brain Organoids.Neuroscience bulletin · 2023Review
- Medulloblastoma and high-grade glioma organoids for drug screening, lineage tracing, co-culture and in vivo assay.Nature protocols · 2023Review
- Modeling Human Brain Tumors and the Microenvironment Using Induced Pluripotent Stem Cells.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Brain tumors are a large and heterogeneous group of neoplasms that affect the central nervous system and include some of the deadliest cancers. Almost all the conventional and new treatments fail to hinder tumoral growth of the most malignant brain tumors. This is due to multiple factors, such as intra-tumor heterogeneity, the microenvironmental properties of the human brain, and the lack of reliable models to test new therapies. Therefore, creating faithful models for each tumor and discovering tailored treatments pose great challenges in the fight against brain cancer. Over the years, different types of models have been generated, and, in this review, we investigated the advantages and disadvantages of the models currently used.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.